Skip to main content
. 2021 Feb 3;10(4):566. doi: 10.3390/jcm10040566

Figure 1.

Figure 1

Illustration of the HER2 signalling pathway. HER2 inhibitor (trastuzumab); HER2/EGFR inhibitors (lapatinib and afatinib); HER2/HER3 inhibitor (zenocutuzumab).